. Author manuscript; available in PMC: 2024 Jul 1.

Published in final edited form as: Pharmacotherapy. 2023 Jun 22;43(7):650–658. doi: 10.1002/phar.2836

Table 2:

Parameter estimates from the previously published model, the final model constructed using external data, and the bootstrap analysis. Model parameter estimates are reported as population mean (% relative standard error) [η-shrinkage] while results from the bootstrap analysis represent the mean (95% confidence interval).

	Published Model	Final Model	Bootstrap Analysis (906/1000 successful)
Parameter
K_e (1/hr) (θ₁)	0.0408 (15%)	0.0255 (11%)	0.0256 (0.0198, 0.0312)
V_d (L) (θ₂)	233 (17%)	314 (16%)	325 (216, 412)
K_a (1/hr) (θ₃)	3.43 (fixed)	3.43 (fixed)	3.43 (fixed)
K_e:CRCL (θ₄)	0.850 (24%)	0.232 (43%)	0.241 (0.031, 0.434)
K_e:WEIGHT (θ₅)	n/a	−0.471 (21%)	−0.470 (−0.653, −0.289)
K_e:FLUCONAZOLE (θ₆)	0.657 (5%)	0.657 (fixed)	0.657 (fixed)
V_d:AGE (θ₇)	0.775 (13%)	0.353 (63%)	0.330 (−0.003, 0.708)
V_d:WEIGHT (θ₈)	n/a	0.025 (33%)	0.025 (0.013, 0.037)
Between-Subject Variability
ω_Ke²	0.262 (40%)	0.118 (25%) [43%]	0.114 (0.055, 0.181)
ω_Vd²	0.329 (35%)	0.303 (13%) [13%]	0.297 (0.227, 0.380)
Residual Error
Additive (ug/L)	3.69 (13%)	3.13 (7%) [7%]	3.13 (2.91, 3.35)